Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133224 · ClinicalTrials.gov registry record · Phase 3
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
A Phase 3 study, sponsored by Cell Genesys.
- Terminated
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT00133224: Clinical Trial Phase 3 study, sponsored by Cell Genesys.
NCT00133224 is a Phase 3 study that was terminated before completion, run by Cell Genesys. The registered enrollment target is 408 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00133224, a Phase 3 study, was terminated before completion, sponsored by Cell Genesys.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases with pain. Patients may have had up to one prior non-taxane chemotherapy treatment.
Interventions
- BIOLOGICAL Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- DRUG Chemotherapy (docetaxel and prednisone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Why NCT00133224 stopped before completion
NCT00133224 is an interventional study that assigns participants to a tested intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Immunotherapy allogeneic GM-CSF secreting cellular vaccine is the first listed.
NCT00133224 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00133224 about?
NCT00133224 is a clinical study titled "Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients". The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone the...
What is the current status of trial NCT00133224?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2005-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00133224?
The interventions under investigation include: Immunotherapy allogeneic GM-CSF secreting cellular vaccine (BIOLOGICAL), Chemotherapy (docetaxel and prednisone) (DRUG).
Who is sponsoring clinical trial NCT00133224?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00133224's enrollment target sits among peer trials
408 911th of 2000 higher than 1,088 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia